North America Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cardiovascular disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet, and Injection), Route of Administration (Oral, and Intravenous), End Users (Hospital, Clinic, and Homecare Settings), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

TIPRE00026139 | Pages: 192 | Pharmaceuticals | Dec 2021 | Type: Regional | Status: Published

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the North America cardiometabolic diseases market.

The impact of COVID-19 continues to surge, and the resulting burden on medical systems has disrupted economies, healthcare systems, and ongoing clinical trials. The COVID-19 pandemic has also triggered the onset of or exacerbate cardiovascular diseases. Also, the COVID-19 is causing serious mental health issues, and the association between depression and cardiovascular disease has long been reported. As per the Cleveland Clinic, approximately 15% of patients with CVD and up to 20% of patients who have undergone coronary artery bypass graft surgery experience major depression. Even mild depression, such as a depressed mood, can increase the relative risk of coronary artery disease. Restrictive measures taken during the COVID-19 pandemic might have increased depression in patients with cardiovascular diseases. Also, many companies have reported a decline in sales of CVD and diabetes drugs in the US. For instance, in Q4 2020, Sanofi’s global diabetes sales decreased 8.4% due to a continued decline in the average US glargine price and some impact from the COVID-19 environment. Also, cardiovascular products sales decreased 7.1%, partially due to the COVID-19 environment. 

Market Overview and Dynamics

The North America cardiometabolic diseases market is projected to reach US$ 43,583.6 million by 2028 from US$ 32,912.1 million in 2021; it is anticipated to grow at a CAGR of 4.1% from 2021 to 2028. The integration of AI is further offering lucrative opportunities for the growth of the worldwide cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Arrowhead Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., Cardax, Inc., and Kowa Company, Ltd.

Reasons to Buy Report

  • To understand the North America cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
  • To comprehend the ever-changing market landscape and stay ahead in competition
  • To efficiently plan merger and acquisition, and partnership deals in the North America cardiometabolic diseases market by identifying segments with the most promising probable sales
  • To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
  • To obtain market revenue forecast of the North America cardiometabolic diseases market based on various segments for the period 2021–2028

NORTH AMERICA CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By Type

  • Cardiovascular disease (CVD)
  • Type 2 diabetes
  • Hypertension
  • Obesity 

By Treatment

  • ACE inhibitors
  • Diuretics
  • Glucophage
  • Others

By Dosage

  • Tablet
  • Injection

By Route of Administration

  • Oral
  • Intravenous

By End Users

  • Hospital
  • Clinic
  • Homecare setting

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Country

  • North America
  • US
  • Canada
  • Mexico

Companies Mentioned

  1. Eli Lilly and Company.    
  2. Bayer AG        
  3. Arrowhead Pharmaceuticals, Inc          
  4. Novartis AG                   
  5. Boehringer Ingelheim International Gmbh
  6. Novo Nordisk A/S       
  7. AstraZeneca                  
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc.
  10. Kowa Company, Ltd.

TABLE OF CONTENTS

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.7        North America Cardiometabolic Diseases market – By Country

2.           North America Cardiometabolic Diseases Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Cardiometabolic Diseases Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.3         Expert Opinions

5.           North America Cardiometabolic Diseases Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing Prevalence of Cardiometabolic Diseases

5.1.2        Innovation in Cardiometabolic Diseases Therapeutics

5.2         Market Restraints

5.2.1        Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)

5.3         Market Opportunities

5.3.1        Technological Advancements in CMD Diagnosis

5.4         Future Trends

5.4.1        Personalized Treatment for CMDs

5.5         Impact Analysis

6.           North America Cardiometabolic Diseases Market – Regional Analysis

6.1         North America Cardiometabolic Diseases Market Revenue Forecast And Analysis

7.           North America Cardiometabolic Diseases Market Analysis – By Type

7.1         Overview

7.2         Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)

7.3         Cardiovascular Disease (CVD)

7.3.1        Overview

7.3.2        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.4         Hypertension

7.4.1        Overview

7.4.2        Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.5         Type 2 Diabetes

7.5.1        Overview

7.5.2        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

7.6         Obesity

7.6.1        Overview

7.6.2        Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.           North America Cardiometabolic Diseases Market Analysis – By Treatment

8.1         Overview

8.2         Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)

8.3         ACE inhibitors

8.3.1        Overview

8.3.2        ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Diuretics

8.4.1        Overview

8.4.2        Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.5         Glucophage

8.5.1        Overview

8.5.2        Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

8.6         Others

8.6.1        Overview

8.6.2        Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

9.           North America Cardiometabolic Diseases Market Analysis – By Dosage

9.1         Overview

9.2         Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)

9.3         Tablet

9.3.1        Overview

9.3.2        Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

9.4         Injection

9.4.1        Overview

9.4.2        Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)

10.        North America Cardiometabolic Diseases Market Analysis – By Route of Administration

10.1      Overview

10.2      Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)

10.3      Oral

10.3.1     Overview

10.3.2     Oral Market Revenue and Forecast to 2028 (US$ Mn)

10.4      Intravenous

10.4.1     Overview

10.4.2     Intravenous Market Revenue and Forecast to 2028 (US$ Mn)

11.        North America Cardiometabolic Diseases Market Analysis – By End User

11.1      Overview

11.2      Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)

11.3      Clinic

11.3.1     Overview

11.3.2     Clinic Market Revenue and Forecast to 2028 (US$ Mn)

11.4      Hospital

11.4.1     Overview

11.4.2     Hospital Market Revenue and Forecast to 2028 (US$ Mn)

11.5      Homecare Settings

11.5.1     Overview

11.5.2     Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)

12.        North America Cardiometabolic Diseases Market Analysis – By Distribution Channel

12.1      Overview

12.2      Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)

12.3      Hospital Pharmacy

12.3.1     Overview

12.3.2     Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

12.4      Retail Pharmacy

12.4.1     Overview

12.4.2     Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

12.5      Online Pharmacy

12.5.1     Overview

12.5.2     Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

13.        North America Cardiometabolic Diseases Market – Geographic Analysis

13.1      North America: Cardiometabolic Diseases Market

13.1.1     Overview

13.1.2     North America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)

13.1.3     North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.4     North America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.5     North America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.6     North America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

13.1.7     North America Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

13.1.8     North America Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)

13.1.9     North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)

13.1.9.1       US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.1       US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.2       US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.3       US: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.4       US: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.5       US: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

13.1.9.1.6       US: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

13.1.9.1.7       US: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

13.1.9.2       Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.1       Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.2       Canada: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.3       Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.4       Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.5       Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

13.1.9.2.6       Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

13.1.9.2.7       Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)

13.1.9.3       Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.1       Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.2       Mexico: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.3       Mexico: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.4       Mexico: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.5       Mexico: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

13.1.9.3.6       Mexico: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

13.1.9.3.7       Mexico: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

14.        Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market

14.1      North America: Impact Assessment of COVID-19 Pandemic

15.        North America Cardiometabolic Diseases Market – Industry Landscape

15.1      Overview

15.2      Growth Strategies in the Cardiometabolic Diseases Market (%)

15.3      Organic Developments

15.3.1     Overview

15.4      Inorganic Developments

15.4.1     Overview

16.        Company Profiles

16.1      Eli Lilly and Company.

16.1.1     Key Facts

16.1.2     Business Description

16.1.3     Products and Services

16.1.4     Financial Overview

16.1.5     SWOT Analysis

16.1.6     Key Developments

16.2      Bayer AG

16.2.1     Key Facts

16.2.2     Business Description

16.2.3     Products and Services

16.2.4     Financial Overview

16.2.5     SWOT Analysis

16.2.6     Key Developments

16.3      Arrowhead Pharmaceuticals, Inc

16.3.1     Key Facts

16.3.2     Business Description

16.3.3     Products and Services

16.3.4     Financial Overview

16.3.5     SWOT Analysis

16.3.6     Key Developments

16.4      Novartis AG

16.4.1     Key Facts

16.4.2     Business Description

16.4.3     Products and Services

16.4.4     Financial Overview

16.4.5     SWOT Analysis

16.4.6     Key Developments

16.5      Boehringer Ingelheim International GmbH

16.5.1     Key Facts

16.5.2     Business Description

16.5.3     Products and Services

16.5.4     Financial Overview

16.5.5     SWOT Analysis

16.5.6     Key Developments

16.6      Novo Nordisk A/S

16.6.1     Key Facts

16.6.2     Business Description

16.6.3     Products and Services

16.6.4     Financial Overview

16.6.5     SWOT Analysis

16.6.6     Key Developments

16.7      AstraZeneca

16.7.1     Key Facts

16.7.2     Business Description

16.7.3     Products and Services

16.7.4     Financial Overview

16.7.5     SWOT Analysis

16.7.6     Key Developments

16.8      Alnylam Pharmaceuticals, Inc.

16.8.1     Key Facts

16.8.2     Business Description

16.8.3     Products and Services

16.8.4     Financial Overview

16.8.5     SWOT Analysis

16.8.6     Key Developments

16.9      Cardax, Inc.

16.9.1     Key Facts

16.9.2     Business Description

16.9.3     Products and Services

16.9.4     Financial Overview

16.9.5     SWOT Analysis

16.9.6     Key Developments

16.10   Kowa Company, Ltd.

16.10.1  Key Facts

16.10.2  Business Description

16.10.3  Products and Services

16.10.4  Financial Overview

16.10.5  SWOT Analysis

16.10.6  Key Developments

17.        Appendix

17.1      About The Insight Partners

17.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 2.             North America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)

Table 3.             North America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)

Table 4.             North America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)

Table 5.             North America Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)

Table 6.             North America Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)

Table 7.             US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 8.             US Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)

Table 9.             US Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)

Table 10.          US Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)

Table 11.          US Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)

Table 12.          US Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)

Table 13.          Canada: Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)

Table 14.          Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 15.          Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 16.          Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 17.          Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 18.          Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)

Table 19.          Mexico Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)

Table 20.          Mexico Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)

Table 21.          Mexico Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)

Table 22.          Mexico Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 23.          Mexico Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 24.          Mexico Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 25.          Organic Developments in the Cardiometabolic Diseases Market

Table 26.          Inorganic Developments in the Cardiometabolic Diseases Market

Table 27.          Glossary of Terms, North America Cardiometabolic Diseases Market

 


LIST OF FIGURES

Figure 1.           North America Cardiometabolic Diseases Market Segmentation

Figure 2.           North America Cardiometabolic Diseases Market Overview

Figure 3.           Cardiovascular Disease (CVD) Segment Held Largest Share Type of North America Cardiometabolic Diseases Market

Figure 4.           North America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)

Figure 5.           North America Cardiometabolic Diseases Market, Industry Landscape

Figure 6.           North America PEST Analysis

Figure 7.           North America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints

Figure 8.           North America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028

Figure 9.           Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)

Figure 10.        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 11.        Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 12.        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 13.        Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 14.        Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)

Figure 15.        ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 16.        Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 17.        Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 18.        Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 19.        Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)

Figure 20.        Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 21.        Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 22.        Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)

Figure 23.        Oral Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 24.        Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 25.        Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)

Figure 26.        Clinic Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 27.        Hospital Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 28.        Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 29.        Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)

Figure 30.        Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 31.        Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 32.        Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 33.        North America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)

Figure 34.        North America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)

Figure 35.        North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)

Figure 36.        US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

Figure 37.        Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

Figure 38.        Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)

Figure 39.        Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market

Figure 40.        Growth Strategies in the Cardiometabolic Diseases Market (%)

S

  1. Eli Lilly and Company.   
  2. Bayer AG             
  3. Arrowhead Pharmaceuticals, Inc    
  4. Novartis AG         
  5. Boehringer Ingelheim International Gmbh
  6. Novo Nordisk A/S            
  7. AstraZeneca         
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc.
  10. Kowa Company, Ltd.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cardiometabolic diseases market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
$1500
Site License
$4000
$2000
Enterprise License
$5000
$2500